Morgan Stanley Bio Line Rx Ltd. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Morgan Stanley holds 197,537 shares of BLRX stock, worth $697,305. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,537

Previous 68,437 188.64%

Holding current value

$697,305

Previous $39,000 171.79%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.53 - $0.87 $68,423 - $112,317	129,100 Added 188.64%	197,537 $106,000
Q2 2024 Oct 17, 2024	SELL	$0.56 - $0.86 $124,833 - $191,708	-222,917 Reduced 76.51%	68,437 $39,000
Q2 2024 Aug 14, 2024	SELL	$0.56 - $0.86 $124,833 - $191,708	-222,917 Reduced 76.51%	68,437 $39,000
Q1 2024 Oct 17, 2024	BUY	$1.03 - $1.56 $229,604 - $347,750	222,917 Added 325.73%	291,354 $326,000
Q1 2024 Aug 16, 2024	BUY	$1.03 - $1.56 $54,685 - $82,825	53,093 Added 22.28%	291,354 $326,000
Q1 2024 May 15, 2024	BUY	$1.03 - $1.56 $54,685 - $82,825	53,093 Added 22.28%	291,354 $326,000
Q4 2023 Aug 16, 2024	BUY	$1.31 - $1.86 $222,469 - $315,872	169,824 Added 248.15%	238,261 $374,000
Q4 2023 Feb 13, 2024	BUY	$1.31 - $1.86 $81,873 - $116,248	62,499 Added 35.56%	238,261 $374,000
Q3 2023 Nov 15, 2023	SELL	$1.23 - $2.45 $104,813 - $208,774	-85,214 Reduced 32.65%	175,762 $319,000
Q2 2023 Aug 14, 2023	BUY	$0.96 - $1.78 $3,901 - $7,233	4,064 Added 1.58%	260,976 $417,000
Q1 2023 May 15, 2023	BUY	$0.56 - $0.89 $2,217 - $3,524	3,960 Added 1.57%	256,912 $228,000
Q4 2022 Feb 14, 2023	SELL	$0.57 - $0.95 $5,475 - $9,126	-9,607 Reduced 3.66%	252,952 $149,000
Q3 2022 Nov 14, 2022	BUY	$0.88 - $1.91 $9,130 - $19,816	10,375 Added 4.11%	262,559 $243,000
Q2 2022 Oct 27, 2022	SELL	$1.06 - $1.82 $20,512 - $35,218	-19,351 Reduced 7.13%	252,184 $323,000
Q2 2022 Aug 15, 2022	SELL	$1.06 - $1.82 $20,512 - $35,218	-19,351 Reduced 7.13%	252,184 $323,000
Q1 2022 Oct 27, 2022	BUY	$1.46 - $2.18 $28,252 - $42,185	19,351 Added 7.67%	271,535 $464,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.18 $16,598 - $24,784	11,369 Added 4.37%	271,535 $464,000
Q4 2021 Feb 14, 2022	BUY	$1.98 - $3.06 $39,675 - $61,316	20,038 Added 8.34%	260,166 $531,000
Q3 2021 Nov 15, 2021	BUY	$2.65 - $3.35 $636,339 - $804,428	240,128 New	240,128 $660,000

Others Institutions Holding BLRX

# of Institutions

Shares Held

3.35M

Call Options Held

46.5K

Put Options Held

6.3K

View Full List

About BioLineRx Ltd.

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $217M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

More about BLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account